Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Cortes-Franco is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1995
Universidad Nacional Autonoma de MexicoClass of 1989
Certifications & Licensure
GA State Medical License 2019 - 2026
TX State Medical License 1996 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Publications & Presentations
PubMed
- CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.Shai Shimony, H Moses Murdock, Julia H Keating, Harrison K Tsai, Archana Sasi
Blood Advances. 2026-02-02 - 1 citationsImproving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey.Fabian Lang, Zack Pemberton-Whiteley, Joannie Clements, Cristina Ruiz, Delphine Rea
Haematologica. 2026-02-01 - Corrigendum to "Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group" [Modern Pathology. 2024;37(2):...Daniel Rivera, Wei Cui, Juehua Gao, Deniz Peker, Qian-Yun Zhang
Modern Pathology. 2026-01-09
Lectures
- Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.2019 ASCO Annual Meeting - 6/1/2019
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Pregnancy Outcomes in Patients Treated with Bosutinib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Rigel Announces Publication of Final 5-Year Data on REZLIDHIA® (Olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & OncologyNovember 17th, 2025- Rigel Announces Publication of Final 5-Year Data on REZLIDHIA® (Olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & OncologyNovember 17th, 2025
- Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
